Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
Publication
, Conference
Levis, MJ; Erba, H; Montesinos, P; Patkowska, E; Cortes, JE; Dombret, H; Perl, AE; Amadori, S; Wang, J; Schlenk, RF; Liu, L; Mostafa Kamel, YM ...
Published in: Blood
November 5, 2024
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
2890 / 2890
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Levis, M. J., Erba, H., Montesinos, P., Patkowska, E., Cortes, J. E., Dombret, H., … Burns, K. (2024). Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx). In Blood (Vol. 144, pp. 2890–2890). American Society of Hematology. https://doi.org/10.1182/blood-2024-207305
Levis, Mark J., Harry Erba, Pau Montesinos, Elzbieta Patkowska, Jorge E. Cortes, Herve Dombret, Alexander E. Perl, et al. “Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx).” In Blood, 144:2890–2890. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-207305.
Levis MJ, Erba H, Montesinos P, Patkowska E, Cortes JE, Dombret H, et al. Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx). In: Blood. American Society of Hematology; 2024. p. 2890–2890.
Levis, Mark J., et al. “Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx).” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 2890–2890. Crossref, doi:10.1182/blood-2024-207305.
Levis MJ, Erba H, Montesinos P, Patkowska E, Cortes JE, Dombret H, Perl AE, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel YM, Imadalou K, Laadem A, Sekeres MA, Burns K. Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx). Blood. American Society of Hematology; 2024. p. 2890–2890.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
2890 / 2890
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology